What question did this study set out to answer?

The study investigates how Augmenter of Liver Regeneration (ALR) influences liver cell proliferation and inflammation through molecular signaling mechanisms.

April 18, 20260 citationsOpen Access

ADAM17, induced by Augmenter of Liver Regeneration via G protein-coupled receptor activation, transactivates epidermal growth factor-receptor and reduces classical IL-6 signaling

CVChristoph Voigt SMSophie Menzel RDRania Dayoub

Key Points

The study investigates how Augmenter of Liver Regeneration (ALR) influences liver cell proliferation and inflammation through molecular signaling mechanisms.
Treatment of hepatoma cell lines and primary hepatocytes with recombinant ALR.
Use of specific inhibitors, siRNA, Western blot, qRT-PCR, and ELISA to analyze signaling pathways.
Investigation of ischemia-reperfusion injury in mice to observe in vivo effects.
ALR induces phosphorylation of the EGF receptor (EGF-R), activating MAPK and PI3K/Akt pathways.
ADAM17 is activated, releasing ligands such as TGFα and amphiregulin from EGF-R, enhancing EGF-R signaling.
ALR reduces IL-6 signaling by cleaving the membrane-bound IL-6 receptor α (gp80), decreasing inflammatory gene expression.

Abstract

Background: Liver regeneration is orchestrated by various cytokines and growth factors, and any imbalance in this process may contribute to liver disease development. Augmenter of Liver Regeneration (ALR), an anti-apoptotic and anti-inflammatory co-mitogen supports regeneration, yet the molecular mechanisms by which ALR regulates proliferation and inflammation remain poorly understood. Methods: Hepatoma cell lines, primary mouse and human hepatocytes, and mice subjected to ischemia–reperfusion injury, were treated with recombinant ALR. Various specific inhibitors, small interfering RNA, immunoprecipitation, Western blot, qRT-PCR and ELISA techniques were utilized to analyze the underlying signaling pathways. Results: ALR induces the phosphorylation of the EGF-receptor (EGF-R), which subsequently activates the MAPK and PI3K/Akt pathways. EGF-R phosphorylation is triggered by EGF-R ligands, such as TGFα, amphiregulin and HB-EGF, which are released from plasma membranes by the sheddase a disintegrin and metalloproteinase 17 (ADAM17) upon ALR activation. Furthermore, ALR-activated ADAM17 cleaves the membrane-tethered IL-6-receptor α (gp80), thereby reducing IL-6-induced STAT3 phosphorylation and the expression of its target genes (e.g. ICAM-1) in vitro and in vivo. The induction of ADAM17 involves the phosphorylation of protein kinase C (PKC) and the tyrosine kinase Src, as well as the activation of a G protein-coupled receptor (GPCR) by ALR. ALR transduction across plasma membranes is achieved by activating a Gαq/11-coupled GPCR, which is known to induce ADAM17 via cytosolic relay molecules PKC and Src. Conclusion: Activation of ADAM17 by ALR: i) transactivates EGF-R signaling upon release of membrane-bound EGF-R ligands, and ii) attenuates classical IL-6 signaling upon gp80 shedding. ALR supports liver regeneration by inducing EGF-R-dependent proliferative (MAPK) and anti-apoptotic (PI3K/Akt) pathways, and reduces IL-6-induced inflammatory gene expression.

Ask AI

Helpful

Bookmark

View Full Paper